Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RPA1 | P27694 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13901607 | 0.85 | CYP2C19 (0.41) | ALDH1A1HPGDKDM4ECYP2C9CYP2C19 | |
| SCHEMBL4012704 | 0.83 | RPA1 (0.43) | ALDH1A1HPGDKDM4ECYP2C9CYP2C19 | |
| SCHEMBL13901649 | 0.78 | TP53 (0.45) | ALDH1A1HPGDKDM4ECNR1CNR2 | |
| SCHEMBL13901598 | 0.78 | CA1 (0.41) | ALDH1A1KDM4EMEN1KMT2ARPA1 | |
| SCHEMBL13901655 | 0.77 | S1PR5 (0.48) | CNR1 | |
| SCHEMBL13901651 | 0.77 | IL2 (0.42) | ALDH1A1HPGDKDM4ECYP2C9CYP2C19 | |
| SCHEMBL13912537 | 0.77 | RAB9A (0.39) | ALDH1A1HPGDKDM4ECYP2C9CYP2C19 | |
| SCHEMBL13901636 | 0.76 | POLB (0.50) | ALDH1A1HPGDCYP2C9CYP2C19POLB | |
| SCHEMBL13901600 | 0.76 | GAA (0.41) | ALDH1A1HPGDKDM4ECYP2C9CYP2C19 | |
| SCHEMBL4015298 | 0.76 | CNR1 (0.43) | ALDH1A1HPGDKDM4EPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | ALDH1A1 1426/4885HPGD 1034/4885KDM4E 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.